Association of COX-2 Promoter Polymorphism with Gastroesophageal Reflux Disease (GERD) and Gastrointestinal Cancers from Iran: An Application for the Design of Early Detection of Cancer and Providing Prognostic Information to Patients in a Clinical Settin by Firouzeh Biramijamal
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1 
Association of COX-2 Promoter Polymorphism 
with Gastroesophageal Reflux Disease (GERD) 
and Gastrointestinal Cancers from Iran: An 
Application for the Design of Early Detection 
 of Cancer and Providing Prognostic 
 Information to Patients in a Clinical Setting 
Firouzeh Biramijamal 
National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, 
Iran 
1. Introduction 
Cyclooxygenase (COX) is a key enzyme responsible for developing several inflammatory 
diseases that may lead to cancer. The COX is an enzyme (EC 1.14.99.1) that it alters 
formation of prostanoids, including prostaglandins, prostacyclin and thromboxane. This 
enzyme converts arachidonic acid to prostaglandin H2 (PGH2) which it precursor of the 
prostanoids. The COX enzyme has two active sites, including heme site and cyclooxygenase 
site. The heme site has proxidase activity that alters the reduction of PGG2 (hydroperoxy 
endoperoxide prostaglandin G2) to PGH2, and, cyclooxygenase site converts arachidonic 
acid into PGG2. It is described three COX isoenzymes, including COX-1, COX-2 and COX-3 
(splice variant of COX-1). COX-1 is a constitutive enzyme and, it is expressed in most 
mammalian cells. Conversely, COX-2 is not expressed in most normal mammalian tissues, 
so, it is an inducible enzyme and it is increased in activated macrophages and during 
inflammation. Inflammation has central role for tumor progression. Presence of 
inflammatory cells can lead DNA-damage-promoting agents. Now, it is clear the 
relationship between inflammation and cancer. Macrophage can be produced Transforming 
growth factor (TGF-ǂ), consequential, permeability of the blood vessel and endothelium is 
increased in the presence of inflammation and in response to prostaglandins which is 
produced by COX-2 enzyme. Therefore, in this microenvironment with inflammatory cells, 
the extracellular matrix degradation can be occurred. Disruption of communication between 
the epithelium and stroma can promote cancer. Induction of Vascular endothelial growth 
factor (VEGF) and angiogenesis are observed after growing tumor cells, and presence of 
hypoxia. So, tumor cells can be received nutrients for more growth, figure 1. 
COX-2 gene expression is enhanced in chronic inflammation. During prolonged 
inflammation, known as chronic inflammation, macrophages are produced TGF-ǂ which it 
promote tumor growth, consequential, hypoxia is observed in microenvironment of tumor  
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Fig. 1. Enhanced expression of COX-2 enzyme promotes tumor growth and cancer 
progression during prolonged (chronic) inflammation. 
cells and inflammatory signals. Hypoxia is pushed the cells to produce Hypoxia-Inducible 
factor (HIF) which stimulates the release of VEGF. So, VEGF binds to VEGF receptors on 
endothelial cells, and leading angiogenesis. Also, matrix metalloproteinases (MMPs) 
upregulates in tumor cells microenvironment to degrade extracellular matrix proteins and 
tumor growth progression.  
It is found that the COX-2 enzyme  up-regulates in various carcinomas and it is described 
the role of COX-2 at an early stage in tumorigenesis. The COX-2 enzyme has been shown as 
an important mediator of proliferation through the increased formation of metabolites such 
as prostaglandin E2. Also, it can be increased the formation of heptanone-etheno (Hε)-DNA 
adducts which are highly mutagenic in mammalian cell lines, and accelerate the somatic 
mutations which are detected in tumorigenesis. It is observed that somatic mutations could 
be arised about 80% of various cancers. 
Enhanced expression of COX-2 has been reported in many types of cancer including breast, 
colon, lung, pancreas, prostate, esophageal during prolonged inflammation, chronic 
inflammation. So, COX-2 is involved in mechanisms of carcinogenesis. COX-2 expression 
and activity is induced by inflammatory signals and carcinogens. COX-2 overexpression is 
associated with cancer development. The COX-2 gene is located at 1q25.2-q25.3. 
The promoter region of the COX-2 gene consists of various transcriptional regulatory 
elements including stimulatory protein 1 (Sp1) binding site. The COX-2 promoter variation 
alters putatively functional transcription factor-binding sites. A variant at position -765 
G→C in promoter of COX-2 gene is involved in modification of COX-2 gene expression. 
Additionally, COX-2 -765G→C genetic variation is linked to change the level of gene 
expression and serum concentrations of C-reactive protein and prostaglandin E2, and, 
inflammatory response is different among individuals with varient alleles, figure 2.  
We describe in this investigation the role of COX-2 genetic variation at -765 of promoter 
region on the risk of gastrointestinal cancers, and also, gastroesophageal reflux (GERD) as  
a risk factor for developing Barrett’s esophagus and then esophageal adenocarcinoma.  
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Fig. 2. Inflammatory response is different among individuals with varient alleles for COX-2 
gene. The G→C substitution at -765 promoter of COX-2 gene can be changed gene 
expression and level of serun concentration of PGE2.  
Colorectal and esophageal cancers are frequent tumor types in gastrointestinal tract 
cancers. The COX-2 enzyme is known to be elevated in chronically inflamed tissues and 
gastrointestinal tumors. The COX-2 gene expression is dependent of interaction of nuclear 
proteins with the COX-2 promoter region. The promoter region of the COX-2 gene plays 
an important role in gene transcription. The single nucleotide polymorphisms in the COX-
2 promoter can modified the binding of nuclear protein and consequentially, the level of 
gene expression and it can be changed susceptibility to cancer including gastrointestinal 
cancer.  
It is described that reflux esophagitis can be changed to Barrett’s esophagus (BE), and 
then, the risk of esophageal adenocarcinoma can be elevated 30- to 125- fold. The gastric 
acid reflux is the cause of esophageal damage in GERD. One of the most effective risk 
factors for inducing Barrett’s esophagus (BE) is Gastroesophageal reflux disease. 
Gastroesophageal reflux disease (GERD) has been reported as a common disease 
worldwide. During reflux in the GERD, induction of the esophageal mucosal damage can 
be occurred due to inflammation. Also, chronic inflammation can be caused of 
progressing chronic esophagitis and premalignant Barrett’s esophagus. The over 
expression of COX-2 gene is during chronic inflammation. It might be developed BE and 
adenocarcinoma (ADC) of the esophagus.  
Barrett’s esophagus epithelium is a premalignant condition prior to esophageal 
adenocarcinoma (ADC). The level of cyclooxygenase-2 enzyme is high in BE epithelium. It is 
shown that COX-2 gene expression is elevated 5-fold in Barrett’s esophagus and 16-fold in 
esophageal adenocarcinoma compared to normal esophageal from healthy individuals. 
Additionally, it is seemed that COX-2 protein expression in the esophagus is independent of 
the degree of inflammation. Also, it is suggested that over expression of COX-2 can be used 
as a biomarker for detection of development of esophageal adenocarcinoma related to 
Barrett’s metaplasia. The over expression of COX-2 is associated with esophageal 
carcinogenesis, and, the condition of tumor aggressive is dependent on the level of COX-2 
protein expression.  
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It is reported that the individuals with -765C allele of the COX-2 gene are susceptible to 
esophageal cancer (both SCC and ADC lesions). 
In addition, chronic inflammation can be caused of esophageal squamous cell carcinoma 
(ESCC) in Iran against western countries. In previous studies, it is reported that 
overexpression of COX-2 is approximately 70% among esophageal squamous cell carcinoma 
(ESCC) from Iranian patients and it is associated with p53 mutations. That investigation 
demonstrated the role of inflammation in carcinogenesis of ESCC in Iran as opposed to 
western countries. Comparing with esophageal cancer especially ESCC, the incidence of 
colorectal cancer (CRC) is relatively low in Iran.  
In this chapter, it is described the association of COX-2 promoter polymorphism with 
gastroesophageal reflux disease (GERD) and gastrointestinal cancers from Iran. It might be 
an application for the design of early detection of cancer and providing prognostic 
information to patients in a clinical setting. In the next pages, it can be find some results for 
this aim.  
2. Materials and methods 
For this purpose, blood and archival cancerous human tissues from ESCC and CRC 
samples, also, esophageal tissue samples from GERD patients were collected. This study 
included 43 formalin-fixed, paraffin-embedded (FFPE) tissues from patients diagnosed with 
ESCC who had undergone curative surgical resection at Imam Khomeini hospital, 17 
colorectal cancer tissues from patients diagnosed with adenocarcinoma who had undergone 
curative surgical resection at Tehran hospital. Then blood samples from eighty-two patients 
with at least one of three important symptoms of GERD (heart burn, acid regurgitation, or 
dysphagia) and erosive reflux esophagitis as diagnosed by endoscopy at the Endoscopy 
Ward of Fayazbakhsh Hospital (Tehran, Iran) and from 103 healthy indivituals were 
selected.  
None of the GERD patients had taken proton pump inhibitors and Nonsteroidal anti-
inflammatory drugs (NSAIDs) during last 4 weeks before beginning of the study. All cases 
underwent treatment with omeprazole as a proton pump inhibitors (PPIs) at 20 mg twice 
daily for 4 weeks. At the end of treatment, second endoscopy was performed for all patients 
and second biopsy was obtained from the previous site. 
The tissue samples from cancer patients were examined by a pathologist according to the 
pathological features of the tumors. Informed consent was obtained from patients and 
healthy individuals followed by completion of a structured questionnaire. Also, this study 
was approved by the National Institute for Genetic Engineering and Biotechnology. 
Hospital records were used to verify age, permanent residence, and ethnicity of 
individuals.  
Genomic DNA was obtained from FFPE tissues in cases and from whole blood of patients and 
healthy individuals by the QIAGEN Flexigen kit or QIAamp DNA minikit (Qiagen,  
Valencia, CA). The extracted DNA was then kept in a -20ºC freezer until further  
use. The COX-2 -765G → C genotyping was performed by PCR, and a fragment of  
228 bp was amplified from DNA isolated from FFPE tissues and blood using  
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the primers COX F: 5′-CATTAACTATTTACAGGGTAACTGCTT-3′ and COX R: 5′-
TGCAGCACATACATACATAGCTTTT-3′. PCR was performed in a 25-µl volume containing 
100 ng DNA template, 50 pmol each primer, 10 mM each dNTP, 2.5 µl Q solution buffer, and 
2.5 µl coral buffer, 1 U/ µl Taq DNA polymerase (HotStarTaq Plus PCR kit from Qiagen). 
Initial denaturation for 10 min at 94ºC was followed by 35 three-step cycles at 94ºC for 30 s, at 
56ºC for 30 s, and at 72ºC for 30 s. The PCR products were subsequently digested with 10 U 
SsiI (Fermentas, Lithuania) for 3 h at 37ºC and separated on a 3% agarose gel. If the CC 
genotype does not cut the PCR product, then there is a 228-bp fragment. If there is a GC, there 
is a cut site, and theoretically it should yield a 228 bp + 168 and 60 bp fragment. The GG 
genotype should give only a 168-bp and 60-bp fragment, figures 3 & 4. To confirm the result of 
PCR-RFLP, selected PCR products were subjected to DNA sequence analysis, figure 5.  
 
                         
3.3 664.8 578.2 N.C M.W
228 bp
 
(a) 
 
 
(b) 
 
Fig. 3. A PCR assay to detect genetic polymorphism at the COX-2 promoter region. A 228 bp 
region of genomic DNA flanking -765 of promoter was amplified using primers which were 
described in the text. (A) The PCR products run on 2% agarose gel for cases numbers 3.3, 
664.8, and 578.2 which were compared with negative control (NA), PCR reaction without 
using genomic DNA to control analysis and possibility of contamination, and a Molecular 
Weight marker (MW). (B) Detection of peak of PCR product with light cycler instrument to 
confirm exact amplification.  
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Fig. 4. Running digested PCR product with SsiI restriction enzyme on 3% agarose gel to 
detect of COX-2 polymorphism at -765 of the promoter region. Lane 1, sample with 
condition of homozygous genotype (G/G); Lane 2, sample with condition of heterozygous 
genotype (G/C); Lane 3, sample with condition of homozygous genotype (C/C); Lane 4, 
negative control (NA) to control the condition of digestion procedure using a reaction 
without restriction enzyme; Lane 5, Molecular Weight marker (MW).  
A
B
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Fig. 5. Electropherogram of DNA sequencing (5′→3′) showing a single base substitution 
(G→C) polymorphism at nucleotide -765 of promoter region. (A) homozygous wild 
genotype (G/G). (B) heterozygous genotype (G/C). (C) homozygous genotype (C/C).  
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Of the 82 esophagitis tissue samples examined in this study for the COX-2 genetic 
polymorphism, frozen samples of 19 patients were available for evaluation of mRNA 
expression for COX-2 gene. The tissues were taken from GERD patients by endoscopic 
biopsy, and then, the samples immersed in RNA later (QIAGEN, Valencia, CA) for RNA 
preservation, where the tissue-containing tubes were kept in a -70°C freezer for later use. 
RNA extraction was performed by the QIAGEN RNeasy Kit, and the RNA samples were 
kept at -70°C. 
For analysis of COX-2 gene expression we used real-time PCR method by Roche Lightcycler 
apparatus. Real-time PCR were carried out in a 25-µl. Reaction volume in Roche capillaries. 
The reaction mixture contains 0.5 µl TaKaRa Ex.taq and 12.5 µl TaKaRa one step Master mix, 
and 0.5 µl TaKaRa RT primers and 7.5 µl TaKaRa RNase free distilled water and forward and 
reverse COX-2 RT primers, each one 10 pmoL, and 2 μL tissue total RNA containing 250 ng 
total tissue mRNA. For internal control, we used ǃ-actin for normalizing the expression  
values between all samples and obtaining comparative expression values relative to ǃ-actin.  
Primers for the reactions were COX-2 forward: 5′-CCTTCCTCCTGTGCCTGATG -3′ and  
reverse: 5′-ACAATCTCATTTGAATCAGGAAGCT-3′, and for ǃ actin: forward: 5′-
GAGACCTTCAACACCCCAGCC-3′ and reverse: 5′-AGACGCAGGATGGCATGGG-3′. For 
each of the real-time amplifications, we prepared a standard curve by running real-time PCR 
with five 10-fold diluted cDNAs as template for COX-2 and ǃ-actin, separately. Therefore, in 
each run for samples we had reactions for COX-2 and ǃ-actin for every sample and one 
standard sample for COX-2, one standard sample for ǃ-actin, and also a negative control for 
COX-2 and a negative control for ǃ-actin. COX-2 to ǃ-actin comparative values were obtained 
as final expression values for each of the tumor tissues and the normal tissues, both for cases 
and healthy controls. COX-2 real-time program consisted of three phases; a reverse 
transcription phase for 5-10 min at 42°C, then an amplification-quantification phase of 50 
cycles of one denaturation step at 95°C for 5 s and one elongation step at 60°C for 35 s, and a 
final phase of melting by increasing the temperature from 65°C to 100°C in 15 s. 
The P values of COX-2 genotype comparisons between cases and control groups were 
considered statistically significant and were below 0.05. This measurement was made by  
2x and Fisher’s exact test. SPSS version 16 was used for all statistical analyses.  
For comparison of COX-2 gene expression means, it is used the Student t-test, and ANOVA 
was applied for comparison of multiple groups in regard to their quantitative expression 
levels. 
3. Results 
Detection of COX-2 genotype for Cases (ESCC, CRC, and GERD/Control) 
We investigated the role of COX-2 -765G→C polymorphism in a case–control study to find 
the distribution of allele frequencies. This polymorphism is known to modulate the 
transcriptional activity and expression of the gene. The study group of 142 patients included 
43 ESCC, 17 colorectal cancers and 82 GERD genotyped for COX-2 polymorphism data. We 
assayed DNA from these samples for the frequency of allelic polymorphism at position -
765G→C in the COX-2 gene. In healthy individuals, the distribution of genotypes fits the 
Hardy–Weinberg equilibrium. The frequency of the C allele was identical among the two 
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groups of cancer patients (P=0.05), but the distribution of the CC genotype was different in 
the two groups (P = 0.001): 23.25% (10 of 43 patients) for ESCC and 5.8% (1 of 17 patients) 
for colorectal cancers. Our results showed that the frequency of the C allele (GC + CC 
genotypes of the COX-2 gene at position -765G→C among the cancer patients and GERD 
patients are high compared with controls. The variation of the allele frequency among 
cancer and GERD groups was significantly different from controls, P = 0.000, and P = 0.001, 
respectively.  
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Fig. 6. Frequency of various genotypes of COX-2 gene among ESCC patients versus healthy 
individuals.  
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Fig. 7. Frequency of various genotypes of COX-2 gene among CRC patients versus healthy 
individuals.  
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Fig. 8. Frequency of various genotypes of COX-2 gene among GERD patients versus healthy 
individuals.  
COX-2 gene expression 
Nineteen patients were enrolled in this study. We found that eight cases (42.1%) were -
765GG (wild type), 10 (52.6%) were -765GC (heterozygous) and 1 (5.2%) was -765CC.  
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Fig. 9. Distribution of nucleotide variation at -765 promoter of COX-2 gene and its effect on 
level of COX-2 over expression. It is showed in this study that COX-2 overexpression is 
remained high among GERD patients after treatment with Omeprazole. It is assumed that C 
allele can be changed the activity of COX-2 enzyme against wild allele.  
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COX-2 mRNA expression was detectable by quantitative real-time RT-PCR in all of 38 tissue 
samples (were obtained from 19 patients in pre and post- treatment statuses). The over 
expression of COX-2 gene remained high after treatment with Omeprazole in the most of 
patients with GERD. The differences was identical among the two groups of investigated 
samples (P=0.07). 
4. Discussion 
The level of the COX-2 enzyme is elevated during inflammation, reflux esophagitis and in 
many types of cancers, including ESCC and colorectal cancer In addition, it is reported that 
COX-2 promoter polymorphisms can modulate the expression of the COX-2 gene. 
Our results in the present study showed that the frequency of the C allele (GC + CC 
genotypes of the COX-2 gene at position -765G→C) among the patients is high compared 
with controls. This investigation could clarify the importance of the COX-2 variants in reflux 
esophagitis and gastrointestinal carcinogenesis in Iran. Our results show that C carriers are 
at higher risk for GERD, ESCC and colorectal cancers. In this study, it is found that the COX-
2 over expression was remained after treatment period with Omeperazole in GERD patients 
with C allele at site of -765 promoter for COX-2 gene. Because, it is described that the level of 
cyclooxygenase-2 enzyme is high in Barrett’s esophagus (BE) epithelium, and also, it is 
shown that COX-2 gene expression is elevated 5-fold in Barrett’s esophagus, so, with regard 
of our results, it can be assumed that the risk of BE developing in the GERD patients with 
COX-2 over expression, after treatment with Omeperazole, might be occurred. This 
hypothesis must be investigated in further study according following up the patients.  
It is shown that G allele at site of -765 promoter for COX-2 gene can reduced COX-2 gene 
expression. Additionally, it is observed that G allele can be changed serum prostaglandin E2 
(PGE2) concentrations. Also, the COX-2 -765G→C polymorphism was demonstrated to 
influence the expression of COX-2 and change the risk of developing adenocarcinoma. 
Chronic inflammation can be developed epithelial hyperplasia, dyslasia, adenoma and 
adenocarcinoma in epithelium of colorectal.  
It is described that COX-2 -765C allele is a protective factor against oral squamous cell 
carcinoma among Taiwan population. However, the COX-2 -765 variants has not effect on 
the risk of head and neck carcinogenesis among Netherland population. Our results showed 
that carriers with C alleles are at higher risk for Gastroesophageal reflux disease (GERD), 
Esophageal squamous cell carcinoma (ESCC) and colorectal cancers. 
It is suggested that genetic variation at -765 of the COX-2 gene may change the over 
expression of COX-2 and therefore result in a higher synthesis of prostaglandins affecting 
the Barrett’s esophagus and carcinogenesis process. In addition, it is described that -765C 
allele of the COX-2 gene affects carcinogenesis of ESCC in Iran. 
Therefore, our findings can change the direction of future study, focusing on the use of 
therapeutic drugs to control and decrease the risk of gastrointestinal cancers among Iranian 
populations. Degree of COX-2 overexpression may be used as an inducible biomarker for 
detection of risk of malignant transformation in GERD patients. 
5. Conclusion 
It is suggested that identification of COX-2 gene expression and polymorphism at -765 of 
promoter can be used for design of early detection of esophageal cancer and providing 
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prognostic information to GERD patients. Measurement of the degree of COX-2 over 
expression can be used as a biomarker for detection of susceptibility of malignant 
transformation among GERD patients. 
Our study observed the association of the -765C allele carrier genotype with risk for ESCC, 
colorectal cancer and GERD in an Iranian population. Iran has a high incidence of ESCC in 
some parts (Golestan Province) and a young age distribution for colorectal cancer, and 
developing GERD symptoms. The results obtained from such studies can be of great 
importance from a therapeutic point of view, as both groups of cancer cells overexpress 
COX-2 and are more sensitive to COX-2 inhibitors. Further investigation of other cancer 
groups including ADC of the esophagus is required to compare with our results. 
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